公开(公告)号：US11780830B2

公开(公告)日：2023-10-10

申请号：US17208887

申请日：2021-03-22

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Sol Park ,  Dong Hoon Kim ,  So Young Kim ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha ,  Eui Chui Lee

IPC: C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D409/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11492335B2

公开(公告)日：2022-11-08

申请号：US17104557

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/10 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D249/08 ,  C07D401/04 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11091479B2

公开(公告)日：2021-08-17

申请号：US16712673

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10562865B2

公开(公告)日：2020-02-18

申请号：US16359984

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D401/04 ,  C07D401/14 ,  C07D249/12 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D249/08 ,  C07D403/04 ,  C07D417/04 ,  C07D407/14 ,  C07D401/10 ,  C07D405/14 ,  C07D413/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11820769B2

公开(公告)日：2023-11-21

申请号：US17368712

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10995086B2

公开(公告)日：2021-05-04

申请号：US16359985

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Sol Park ,  Dong Hoon Kim ,  So Young Kim ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha ,  Eui Chul Lee

IPC: C07D409/06 ,  C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10899719B2

公开(公告)日：2021-01-26

申请号：US16721020

申请日：2019-12-19

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D403/04 ,  C07D249/08 ,  C07D401/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).